Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 12:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Breast Imaging Clear all
Active, not recruiting Phase 2 Interventional

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

NCT05554380
View directory record Official record
Conditions
Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipatasertib, Magnetic Resonance Imaging, Paclitaxel
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
207
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 167 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Completed No phase listed Observational

Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer

NCT02666378
View directory record Official record
Conditions
Breast Cancer
Interventions
Cardiac Magnetic Resonance Imaging (CMR), Echocardiogram (ECHO)
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Sep 23, 2026, 12:41 PM EDT
Recruiting Phase 1 Interventional

Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors

NCT07660055
View directory record Official record
Conditions
Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Gastric/Gastroesophageal Junction (GEJ) Cancer, Bladder Cancer
Interventions
[68Ga]Ga-DWJ155, [177Lu]Lu-DWJ155
Diagnostic Test · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Active, not recruiting No phase listed Observational

Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT

NCT03846167
View directory record Official record
Conditions
Breast Cancer
Interventions
Imaging Drug FluorThanatrace (FTT)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Active, not recruiting No phase listed Observational

Non-contrast DWI for Supplemental Screening

NCT03607552
View directory record Official record
Conditions
Breast Cancer
Interventions
Non-contrast DWI, Non-contrast MRI
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
269 participants
Timeline
2018 – 2029
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Terminated Not applicable Interventional

Intraoperative Use of an Optical Coherence Tomography (OCT) Imaging System to Guide Additional Margin Cavity Shaves in Breast Conserving Surgery (BCS)

NCT04314700
View directory record Official record
Conditions
Breast Cancer Female
Interventions
OCT- based investigational imaging device
Device
Lead sponsor
Perimeter Medical Imaging
Industry
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cottonwood, Arizona
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 23, 2026, 12:41 PM EDT
Completed No phase listed Observational Results available

A Post-Market Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System

NCT03300206
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Breast Biopsy
Device
Lead sponsor
Hologic, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Phoenix, Arizona • Kensington, Maryland • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Sep 23, 2026, 12:41 PM EDT
Active, not recruiting Phase 1 Interventional

Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer

NCT02453620
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Johns Hopkins Breast Cancer Program Longitudinal Repository

NCT01937039
View directory record Official record
Conditions
Breast Cancer, Benign Breast Disease
Interventions
Sample collection
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
810 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sonography of the Nipple Areolar Complex

NCT06441188
View directory record Official record
Conditions
Healthy
Interventions
Thin layer conventional ultrasound coupling gel, Thick layer of conventional ultrasound coupling gel, Thin conventional ultrasound coupling gel pad, Thick conventional ultrasound coupling gel pad
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 23, 2026, 12:41 PM EDT
Completed Early Phase 1 Interventional

Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy

NCT02679586
View directory record Official record
Conditions
Breast Cancer
Interventions
Diffusion weighted MRI
Device
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Sep 23, 2026, 12:41 PM EDT
Withdrawn Phase 1 Interventional

Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung

NCT01741597
View directory record Official record
Conditions
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Liver Metastases, Lung Metastases, Recurrent Breast Cancer, Recurrent Pancreatic Cancer, Stage IV Breast Cancer, Stage IV Pancreatic Cancer
Interventions
dynamic contrast-enhanced magnetic resonance imaging, pharmacological study, tumor-homing peptide iRGD
Procedure · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Sep 23, 2026, 12:41 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

3D Ultrasound Microvessel Imaging for Breast Masses

NCT04925817
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Electronic Health Record Review, Ultrasound Microvessel Imaging
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Sep 23, 2026, 12:41 PM EDT
Active, not recruiting Phase 2 Interventional

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study

NCT04316117
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Carcinoma, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
98
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Suspended No phase listed Observational

Safety, Ultrasound Conspicuity, and Migration of Twinkling Markers in Patients With Locally Advanced Breast Cancer

NCT05547347
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Resectable Breast Carcinoma
Interventions
Magnetic Resonance Imaging, Mammogram, Ultrasound, Ultrasound-Guided Biopsy, Twinkle marker
Procedure · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts

NCT04854304
View directory record Official record
Conditions
Breast Diseases
Interventions
Fast Breast Abbreviated Magnetic Renounce Imaging
Diagnostic Test
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
40 Years to 75 Years · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Completed Phase 2 Interventional Results available

Denosumab and MRI Breast Imaging

NCT02613416
View directory record Official record
Conditions
Breast Cancer
Interventions
Denosumab
Drug
Lead sponsor
Alison Stopeck
Other
Eligibility
Up to 75 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Sep 23, 2026, 12:41 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

NCT04345913
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Copanlisib Hydrochloride, Eribulin Mesylate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
43
States / cities
Sacramento, California • Derby, Connecticut • Fairfield, Connecticut + 34 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Low-field MRI for Breast Cancer Screening

NCT05486520
View directory record Official record
Conditions
Breast Benign, Malignant Neoplasm of Breast, Breast Malignant Tumor
Interventions
Magnetic Resonance Imaging (MRI)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 80 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 23, 2026, 12:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise Programs in Healthy Young Women at Increased Risk of Developing Breast Cancer

NCT00892515
View directory record Official record
Conditions
Breast Cancer, Healthy, no Evidence of Disease
Interventions
exercise intervention, counseling intervention, gas chromatography, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, mass spectrometry, physiologic testing, questionnaire administration, survey administration, dual x-ray absorptometry, magnetic resonance imaging, study of high risk factors
Behavioral · Other · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Sep 23, 2026, 12:41 PM EDT
Completed Not applicable Interventional Results available

The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease

NCT01687790
View directory record Official record
Conditions
Breast Abnormalities
Interventions
molecular breast imaging (Discovery)
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2016 · Synced Sep 23, 2026, 12:41 PM EDT
Completed Not applicable Interventional

Digital Mammography Screening Trial (ACRIN6652)

NCT00008346
View directory record Official record
Conditions
Breast Cancer
Interventions
Full Field Digital Mammography, Screen Film Mammography
Diagnostic Test
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
Up to 120 Years · Female only
Enrollment
49,528 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
31
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 23, 2026, 12:41 PM EDT
Recruiting Not applicable Interventional

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

NCT05977036
View directory record Official record
Conditions
Metastatic Breast Cancer, Unresectable Breast Cancer
Interventions
DiviTum® TKa assay, CDK4/6 + Endocrine therapy
Device · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 23, 2026, 12:41 PM EDT
Recruiting Not applicable Interventional

Breast Elasticity Imaging During Neoadjuvant Chemotherapy

NCT04824027
View directory record Official record
Conditions
Breast Cancer
Interventions
Harmonic motion imaging
Procedure
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 28, 2025 · Synced Sep 23, 2026, 12:41 PM EDT